PharmaCyte Biotech invests $3M in TNF Pharma for convertible preferred and warrants linked to LightSolver license

PharmaCyte Biotech, Inc.

PharmaCyte purchased $3M of TNF Series H convertible preferred shares (convertible at $5) and warrants for 600,000 common shares at $5 exercise price.
Investment supports TNF's license with LightSolver for a light-speed computing platform for cryptocurrency mining and blockchain.
TNF plans to change its name and ticker to reflect the new strategy; warrants expire 5 years after stockholder approval.
Preferred shares carry 7% annual dividend (15% on trigger events) and price-based anti-dilution adjustments.
PharmaCyte reports total assets over $55M as of April 30, 2025, and will use cash for this investment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.